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Introduction 
Respiratory syncytial virus (RSV) infection is one of the most 
common causes of bronchiolitis and pneumonia in infants who 
require hospitalization worldwide. The prevalence of hospitalization 
for RSV infection is highest in infants less than 6 months old, and 
decreases after two years of age.1)
The risk of severe RSV infection with significant morbidity and 
mortality is greatest in premature infants, infants with chronic 
lung disease, immune deficiency, and hemodynamically significant 
congenital heart disease (HS-CHD).2)3) HS-CHD patients often have 
several pathophysiological issues such as altered pulmonary blood 
flow, cyanosis, pulmonary hypertension, and ventilation-perfusion 
mismatch, which can exacerbate lower respiratory tract infections. 
Therefore, RSV infection in those infants is associated with longer 
hospitalization, higher admission rates to the intensive care unit 
(ICU), and more frequent requirement for mechanical ventilation.4-6) 
Recent studies have suggested that among the infants with 
congenital heart disease (CHD) who are hospitalized with RSV 
infection, 33% will require treatment in an ICU, and as many as 
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7.3% will die as a result of complications from RSV infection. The 
mortality rates associated with RSV infection in CHD have been 
reported significantly higher than in infants without underlying 
diseases.7-9) 
For the past 10 years, the humanized monoclonal antibody, 
palivizumab, has been used as prophylaxis for serious RSV infection 
in high risk infants, and has resulted in a significant reduction in 
hospitalization rates for children <24 months of age suffering from 
HS-CHD.10) Reflecting the global trend, Korean guidelines by the by 
Korean National Health Insurance Review and Assessment Service, 
have approved the use of palivizumab in children <1 year of age 
with HS-CHD since 2009 (Table 1). These criteria, as suggested 
by Feltes et al.,7)11) have been applied in the recommendation of 
indicated RSV prophylaxis in many countries, but only up to 2 years 
of age. This is the first study to evaluate the compliance with the 
Korean guideline on prophylactic treatment for RSV in pediatric 
CHD patients. We retrospectively analyzed current data on RSV 
prophylaxis to determine the prevalence of morbidity in children 
with CHD in Korea, who developed RSV infection despite receiving 
prophylaxis as per the Korean guidelines.
Subjects and Methods 
We conducted a retrospective, multicenter study at six major 
tertiary care children’s hospitals (Ajou University School of Medicine, 
Sejong General Hospital, Pucheon, Seoul National University 
Children’s Hospital, Sungkyunkwan University Samsung Medical 
Center, Seoul, Ulsan University Asan Medical Center and Yonsei 
University Cardiovascular Center, Korea) during 6-year seasonal 
period, from 1st October 2009 to 31st March 2015. We examined 
hospital medical records of all children with CHD who had received 
palivizumab according to the prophylaxis guideline and clinical 
decision after approval of the Investigated Research Board (AJIRB-
MED-MDB-11-351). A total of 466 children with CHD received 1-5 
injections of palivizumab (15 mg/kg) by intramuscular injection 
every 30 days, over one RSV season (October to February). CHD 
were identified by code based on the 10th revision of International 
Classification of Diseases and Related Health Problems (ICD-10). 
The Korean guidelines for RSV prophylaxis suggest that children 
less than 1 year of age with HS-CHD are most likely to benefit 
from prophylaxis. HS-CHD was defined as uncorrected or palliated 
cyanotic CHD, or acyanotic CHD associated with documented 
pulmonary hypertension, and/or a requirement for medication to 
manage congestive heart failure (CHF). 
Information collected for each patient included date of birth, age 
at first dose, follow up period, gender, structural type of CHD, and 
the number of palivizumab injections received before and after RSV 
infection. Additional data reviewed included the time between the 
actual start of treatment and the recommendation in the national 
guideline (October or the first month of life, if the child was born 
during the RSV season). Any underlying diagnoses of chromosomal 
defects, prematurity and low birth weight and status of 
cardiovascular surgery undergone, that involved cardiopulmonary 
bypass, were reviewed.
We also investigated the patients hospitalized for RSV infection 
despite receiving palivizumab; factors included their age and 
calendar month at RSV infection, and factors related to infection 
severity. For infection severity, we reviewed their visit to the 
emergency department and ICU admissions, hospital and ICU 
length of stay, oxygen requirements, mechanical ventilation use, 
and delay of elective operation. According to different types of 
heart disease, the rate of RSV infection, all-cause and RSV related 
mortality, and doses of palivizumab were analyzed. 
RSV infection was confirmed by direct fluorescent antibody 
staining, culture, or reverse-transcriptase polymerase chain reaction 
on nasopharyngeal swabs or aspirates according to policy of each 
center. We noted the number of patients with breakthrough RSV 
infection and mortality, by comparison to doses of palivizumab 
prophylaxis according to type of CHD.
Data were entered into the Statistical Package for the Social 
Sciences (version 18.0, SPSS Inc., Chicago, IL, USA) program and 
analyzed using descriptive statistics. All continuous variables were 
analyzed using standard descriptive statistics with mean±standard 
deviation values. Statistical significance was defined as p<0.05. 
Table 1. The Korean guideline for the use of palivizumab prophylaxis for infants with congenital heart disease (last updated in 2009)
Children ≤1 year of age with hemodynamically significant congenital heart disease at the start of RSV season (from October to March)
1. Infants who are receiving medication for congestive heart failure 
2. Infants with moderate to severe pulmonary arterial hypertension 
3. Infants with cyanotic heart disease
RSV: respiratory syncytial virus 
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Results 
From October 2009 to March 2015, 466 patients received RSV 
prophylaxis with palivizumab at six major pediatric cardiac centers 
in Korea. The mean age of patients at the start of prophylaxis was 
2.9±2.8 months (range, 0-11.2 months), and the mean follow-up 
period was 24.3±16.4 months. The male to female ratio was 1.03 
(male:female=237:229). 
The main indication for RSV prophylaxis in this study was 
moderate to severe pulmonary hypertension (n=213; 45.7%), 
followed by cyanotic heart disease (n=196; 42.1%) and CHF requiring 
medication (n=115; 24.7%). A total of 4 patients (0.9%) (3 with HCM 
and 1 with mitral stenosis) had received RSV prophylaxis according 
to the clinician’s recommendation, regardless of exclusive criteria 
of the Korean guideline of RSV prophylaxis for CHD patients. 
Co-morbidities other than CHD were found in 127 patients 
(27.3%): chromosomal anomalies were found in 65 (13.9%), low 
birth weight baby in 33 (7.1%), and prematurity in 35 patients 
(7.5%). 
Most patients (n=442; 94.8%) underwent either palliative or 
definitive cardiac surgery before (60.3%) and after (39.7%) the 
start of palivizumab vaccination. After cardiac surgery that involved 
cardiopulmonary bypass, 5 (1.1%) patients received one additional 
dose immediately postoperatively (Table 2). 
The mean number of received injections was of 3.7±1.9 per patient 
(range, 1-10). Only 146 patients (31%) received more than five 
injections following the guidelines, whereas the majority (n=320; 
69%) received less than four injections, including 166 patients 
(36%) who received only one injection (Fig. 1). Among the patients, 
7 who had been born prematurely received palivizumab injections 
until they reached 2 years of age, according to the Korean guideline 
for prematurity. There were 182 patients (39%) who did not start 
the first injection of palivizumab at the recommended time – in the 
first October or the first month of life if the child was born during 
the RSV season – according to the guideline, with an average delay 
of 2.7±2.6 months (range, 1-4 months) (Figs. 1, 2, and 3).    
Among the 466 patients with CHD during the follow up 
period, 39% had no respiratory symptoms, 61% had respiratory 
symptoms. Of the patients having respiratory symptoms, 49% had 
non-RSV respiratory infections and 12% had RSV infection. Fifty-
seven patients (12.2%) were hospitalized with breakthrough RSV 
bronchiolitis after prophylaxis. Other respiratory virus infections 
with rhinovirus, parainfluenza virus, influenza virus, adenovirus, 
metapneumovirus, bocavirus, coronavirus, and Epstein-Barr virus 
affected 24 patients (42.1%). Prophylactically treated CHD patients 
Table 2. Patients’ characteristics (N=466)
Characteristics Numbers (%)
Male:female 237 (50.9%):229 (49.1%)
Age at first injection of palivizumab (month) 2.9±2.8 (range, 0-11.2)
Mean doses of palivizumab underwent cardiovascular surgery (n=442) 3.7±1.9 (range, 1-10) (94.8%)
Co-Morbidities 
Prematurity 35 (7.5%)
Low birth weight 33 (7.1%)
Chromosomal anomalies or syndromes 65 (13.9%)
RSV bronchiolitis 57 (12.2%)
Respiratory infection associated with other viruses requiring in-hospitalization treatment 40 (8.6%)
Total deaths 30 (6.4%)
RSV: respiratory syncytial virus 
Fig. 1. The number of patients according to palivizumab injections 
(N=466).  The mean number who received injections was 3.7±1.9 per 
patient (range, 1-10). Only 146 patients (31%) received more than five 
injections because of prematurity, whereas the majority (n=320; 69%) 
received less than four injections, including 166 patients (36%) who 
received only one injection.
1 injection
166 (36%)
2 injections
57 (12%)
3 injections
38 (8%)
4 injections
59 (13%)
5 injections
124 (27%)
≥6 injections
22 (4%)
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with RSV infection who required hospitalization had received an 
average of 3.6±1.9 injections (range, 1-8). The mean age of these 
patients was 7.9±5.7 months (range, 1.6-23.8), with a maximum 
(86%) experiencing frequent RSV infections between October and 
the following January (RSV season; Fig. 3). These CHD patients 
were diagnosed as systemic-pulmonary shunt defects (42.1%), 
univentricular heart (10.5%), pulmonary hypertension (3.5%), left 
side outflow obstruction (12.2%), right side outflow obstruction 
(1.7%), Tetralogy of Fallot (22.8%), other complex cyanotic heart 
disease (5.2%) and cardiomyopathy (5.2%). Patient information 
is displayed in Tables 3 and 4. About 60% of the patients visited 
the emergency room and were hospitalized for an average of 
15.7±5.2 days (range, 3-60 days). One-fourth of the patients 
(24.6%) required admission to the ICU; 8 patients (14%) needed 
supplemental oxygen, and 5 patients (8.8%) needed mechanical 
ventilation; however, extracorporeal membrane oxygenation 
was not required for any patient (Table 3). Three patients were 
hospitalized twice, once before and once after the 1-year-old 
check-up. Total of 5 patients were diagnosed as RSV infection after 
the first year follow-up, including these 3 patients. 
Comparison of mortality data between RSV infection and doses 
of palivizumab according to the structural type of CHD, revealed 
that one-third of the children (n=176; 37.7%) were classified as 
having shunt lesions with pulmonary hypertension. Among these, 
24 patients (13.6%) were diagnosed with RSV infection. There were 
7 in-hospital deaths of patients with shunt lesions, 3 of which 
were related to RSV infection. In the group of 59 patients (12.7%) 
with univentricular heart defects, there were 9 deaths, but none 
Table 3. Characteristics of prophylactically treated CHD patents 
requiring hospitalization for RSV infection (N=57)
Characteristics Numbers
Total number of injections (shots, mean±SD ) 3.6±1.9 (range, 1-8)
Number of injections prior to RSV infection 1.4±1.6 (range, 0-6)
Number of injections post to RSV infection  2.1±1.7 (range, 0-5)
Age at RSV infection (months, mean±SD) 7.9±5.7 (range, 1.6-23.8)
Co-Morbidities 13 (22.8%)
Prematurity 6 (10.5%)
Low birth weight 2 (3.5%)
Chromosomal anomalies or syndromes  5 (8.8%)
Other respiratory viral co-infections 24 (42.1%)
Visits to emergency room 33 (57.9%)
Days of hospitalization (days, mean±SD) 15.7±5.2 (range, 3-60)
Required oxygen 8 (14.0%)
Delay of elective surgery 4 (7.0%)
ICU admission 14 (24.6%)
Ventilator requirement 5 (8.8%)
Deaths related to RSV infection 5 (8.8%)
Simple left-to-right shunt lesions 3
 Tetralogy of Fallot 1
Hypertrophic cardiomyopathy 1
CHD: congenital heart disease, RSV: respiratory syncytial virus, SD: stan-
dard deviation, ICU: intensive care unit
Fig. 2. The number of patients starting treatment during the 
recommended time of the year, in accordance with the national guideline. 
There were 182 patients (39%) who did not start the first injection of 
palivizumab at the right time according to the guideline, with an average 
delay of 2.7±2.6 months (range, 1-4 months).
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Fig. 3. The serial infection rate of RSV according to each calendar month. 
Fifty-seven patients (12.2%) were hospitalized with breakthrough RSV 
bronchiolitis after prophylaxis. The mean age of these patients was 7.9±5.7 
months (range, 1.6-23.8), and most (86%) experienced frequent RSV 
infections between October and the following January. RSV: respiratory 
syncytial virus.
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was related to RSV infection. The group with HCM had larger 
breakthrough rate of RSV infection: out of 3 patients, 2 (66.6%) 
were treated for RSV infection. In addition, of the 2 deaths reported 
in this group, 1 was related to RSV infection.
During follow-up, all-cause mortality was reported as 30 for this 
group (6.4%). In 19 patients who died from cardiac issues, 3 deaths 
were from early postoperative complications; 11 patients died from 
other morbidities, including 5 patients (1.1%) due to RSV infection 
(Table 4).
Discussion
The effectiveness of prophylactic palivizumab for prevention of 
RSV infection in CHD patients was shown by a randomized controlled 
study in 1998.7) Palivizumab, a humanized monoclonal antibody 
against RSV, has been the gold standard for RSV prophylaxis in 
high risk groups, and recently was shown by a Cochrane meta-
analysis to have significantly reduced the hospitalization rate of 
infected patients.10) The study showed a 45% relative reduction in 
RSV hospitalization among high risk children receiving palivizumab 
(9.7% vs. 5.3%; p=0.003). before the palivizumab era, about more 
than 10% of all CHD infants required hospital admission for RSV 
infection and some needed intensive care; however, palivizumab 
vaccination at the start of RSV season has been proven to reduce 
the rate of hospitalizations by half (~5%).7)12)13)
In Korea, according to the biweekly reports from the Korea 
Centers for Disease Control and Prevention, the seasonal outbreaks 
of RSV infection occur during the winter months, namely 
September through March. Almost all children are susceptible 
to RSV infection until they reach the age of 2 years, and on an 
average, nearly half will experience two episodes of infection.2)9) 
Prior to the palivizumab era (from 2003 to 2006), in a study of 
213 patients diagnosed with lower respiratory infection, 45 CHD 
patients (21.1%) were hospitalized due to RSV infection, 22 (48.9%) 
were treated in the ICU, 12 (26.7%) required mechanical ventilation, 
and 2 (4.4%) died; however, no deaths occurred among non-CHD 
patients.14)
In our study, the rate of mortality related to RSV infection (1.1%) 
was reduced significantly but was still a threat to infants with HS-
CHD even after palivizumab injection, because the monoclonal 
antibody tends to attenuate but not eradicate RSV disease.5)9)15-17)  
Moreover, the rate of RSV-associated hospitalization of children 
<12 months old with HS-CHD who received more than one 
prophylactic injection was 12.5%, which was relatively higher than 
in previous reports from other countries (0.46% to 5.3%).18) One-
Table 4. Comparison data of death, RSV infection, and the number of palivizumab injections according to underlying heart diseases (N=466)
Heart diseases Number of patients (%)
Number of RSV 
positive (%) Total deaths
 Deaths related
 to RSV
Average number of 
palivizumab injections
Systemic-pulmonary shunt defects
 (AVSD, ASD, VSD)
176 (37.7) 24 (13.6) 7 3 2.51
Tetralogy of Fallot 114 (24.4) 13 (11.4) 6 1 3.37
Univentricular heart 59 (12.7) 6 (10.2) 9 - 3.63
Left side outflow obstructions (AS, CoA, IAA) 43 (9.2) 7 (16.3) - - 2.77
Right side outflow obstructions (PA, PS) 23 (4.9) 1 (4.3) - - 3.55
PH
(Prematurity, Down syndrome with
 small L-R shunt defect)
13 (2.8) 2 (15.4) 3 - 3.85
Other complex cyanotic heart disease
Complete TGA with/without VSD 15 (3.2) 1 (6.7) - - 2.98
TAPVR 14 (3.0) 1 (7.1) 2 - 3.07
Anomalous LCA from pulmonary artery 3 (0.6) 1 (33.3) - - 3.67
Cardiomyopathy 
Hypertrophic cardiomyopathy 3 (0.6) 2 (66.6) 2 1 3.67
Dilated cardiomyopathy 5 (1.1) 1 (20.0) - - 2.59
Total 466 57 (12.2) 30 (6.4) 5 (1.1) 3.71
RSV: respiratory syncytial virus, AVSD: atrioventricular septal defect, ASD: atrial septal defect, VSD: ventricular septal, AS: aortic stenosis, CoA: coarctation 
of aorta, IAA: interrupted aortic arch, PA: pulmonary atresia, PS: pulmonary stenosis, PH: pulmonary hypertension, TGA: transposition of great arteries, 
TAPVR: total anomalous pulmonary venous return, LCA: left coronary artery
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fourth of the patients were admitted to the ICU with RSV infection, 
and 3 patients were hospitalized for longer than 4 weeks. This 
could relate to incomplete vaccination, which would point to a lack 
of compliance with the guideline, as well as increased testing for 
RSV.5)7)11)19-23)
Many cases started prophylaxis either earlier (n=70, 15%) 
or later (n=182, 39%) than the recommendation, and it can be 
argued that delays in identifying patients at risk could have 
affected the outcome.23) Monthly injections of up to five injections 
are recommended once patients start treatment; however, the 
majority (69%) of patients in this study received less than four, 
including 36% who received only one injection. Therefore, factors 
involved in effective prophylactic treatment include ensuring that 
treatment is initiated at the right time, and that children with CHD 
are identified and followed up. Missing or delayed injections may 
lead to increased rates of re-hospitalization, making it essential to 
adhere to prophylactic guidelines.24)25) 
According to many studies that have reported advantages in 
socio-economic aspects of prophylaxis of RSV infection in CHD 
patients under the age of 2 years, recommendations from the 
guidelines of Canada, Japan, Germany, and Austria for the use of 
palivizumab have included children younger than 24 months of 
age.8) In contrast, the Korean guideline has recommend 12 months 
as the upper age limit. Our study noted that 3 patients were 
hospitalized with RSV infection after 1 year of age, who were not 
treated after the recommended age of 12 months. 
The majority of CHD patients in this study (35.6%) had shunt 
lesions with pulmonary hypertension, and 94.8% had undergone 
corrective surgery. Because the Korean guideline for the use of 
palivizumab in infants with CHD limits the vaccination to the infants 
who are receiving medication for congestive heart failure, patients 
who showed improvement of heart failure after cardiovascular 
surgery usually had terminated medication, and therefore, were 
not eligible for additional vaccinations. Moreover, RSV pneumonia 
is associated with a high risk of postoperative complications.4)26)27) 
In this study, there were 5 deaths related to RSV infection; of 
these, underlying heart diseases for 3 among the 5 deaths were 
associated with simple left-right shunt lesion. The American 
Association of Pediatricians has recommended administration of 
another injection of palivizumab (15 mg/kg) as soon as possible in 
postoperative patients because serum palivizumab levels decrease 
by 58% after cardiopulmonary bypass.15)16)28) Therefore, it is essential 
to supplement this guideline, as well as adhere to the existing 
guideline, ensuring that treatment is started at the right time and 
that an additional postoperative injection is given immediately. The 
emphasis should be the identification of children with CHD. 
Cardiomyopathies as well as other structural heart diseases are 
major risk factors for RSV hospitalization in infants with CHD.20)29)30) 
Furthermore, in our study, HCM patients were placed into the 
high risk group with respect to RSV infection because 66.6% 
(n=2) had contracted RSV infection and 20% (n=1) of all RSV-
related mortality occurred in the HCM group. Stagnant pulmonary 
flow due to cardiomyopathy results in significantly abnormal 
hemodynamics with perivascular infiltrates, leading to altered 
vascular tone and permeability changes in the alveolar-capillary 
interface, which is further exaggerated by the inflammation caused 
by RSV.29) Therefore, the USA, UK, Japan, France, and Austria have 
adopted the recommendations for infants with cardiomyopathy as 
co-morbidity.8) These findings should be taken into consideration 
when deciding which children should receive prophylaxis.
There were a few of limitations to this study. A recent systematic 
review of the cost-effectiveness of palivizumab prophylaxis 
compared with no prophylaxis in infants and young children with 
CHD showed a favorable trend, but were not addressed in this 
study.30) We are also still collecting data for further study of the 
treatment effect of palivizumab against RSV in a large population, 
which is warranted.
For CHD patients in Korea, small doses and omitting or delaying 
palivizumab prophylaxis were found in major pediatric centers 
during the 2009-2015 RSV seasons. Even though the current data 
on RSV prophylaxis has been collected for infants with CHD in 
Korea, the data might actually be helpful for CHD patients if the 
Korean guideline would be extended to children up to 24 months 
of age with HS-CHD, including cardiomyopathy, and postoperative 
CHD patients. We recommend that the guideline should be updated 
based on the key findings: (i) the risk of hospitalization due to RSV 
infection remains high among children with CHD, (ii) children 
with CHD exhibit a higher rate of morbidity despite prophylactic 
treatment than that reported in recent studies,11)18-22) and (iii) 
since the RSV season of Korea is not different with that of other 
countries, the national guideline might be regarded as outdated by 
international guidelines.23) In Korean guidelines, the patient group 
with HCM was not supported financially. Thus, only a few patients 
with HCM were included because patients who had received 
palivizumab injection were rare.  
This is the first and largest study to evaluate compliance 
according to the Korean guideline for prophylactic treatment, and 
to determine that morbidity and mortality due to RSV infection 
is still significant in children with CHD. According to the Korean 
guidelines, the risk of RSV infection remains significant among 
children with hemodynamically insignificant CHD, cardiomyopathy, 
and children above 1 year-old with HS-CHD. 
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